Company profile
CNBX Pharmaceuticals Inc.
OTC: CNBX · Healthcare · Biotechnology
#1161 of 1,417 Healthcare companies by revenuebottom-decile growth
EA Score
19DFH 9DQ 38GM 4SS 29
v0.1 · 65/100 weight · provisional
↑ listing tenure, disclosure history · ↓ workforce scale, revenue growth (YoY)
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$314.0k
Employees
1
as of 2026-08-29
Market cap
$13.0k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$314.0k-$314.0k2025
Operating income-$271.7k-$271.7k2025
Total assets$18.4k$18.4k2025
Liabilities$491.2k$491.2k2016
Equity-$2.5M-$2.5M2025
Revenue trend
FY2017 – FY2025 · USD
FY17
FY19
FY20
FY21
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CNBX Pharmaceuticals Inc.’s revenue?
CNBX Pharmaceuticals Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
ARYx Therapeutics, Inc.——VioQuest Pharmaceuticals, Inc.——Golden Developing Solutions, Inc.——Vaxxinity, Inc.——Thunder Energies Corporation——Eco Science Solutions, Inc.33DNeighbors
Montgomery →Key facts
CEOEyal Barad
SectorHealthcare
IndustryBiotechnology
HeadquartersBethesda, MD
ExchangeOTC: CNBX
Employees1
IPO date2007-09-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.